Lindsay M. Morton

Lindsay M. Morton

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Blood
Verified
Journal Article
Open access
PDF file
LMLindsay M. Morton
Lindsay M. Morton
SWSophia S. Wang
Sophia S. Wang
SDSusan S. Devesa
Susan S. Devesa
PHPatricia Hartge
Patricia Hartge
DWDennis D. Weisenburger
Dennis D. Weisenburger
MLMartha S. Linet
Martha S. Linet
Because the causes of most lymphoid neoplasms remain unknown, comparison of incidence patterns by disease subtype may provide critical clues for future etiologic investigations. We therefore conducted a comprehensive assessment of 114 548 lymphoid neoplasms diagnosed during 1992-2001 in 12 Surveillance, Epidemiology, and End Results (SEER) registries according to the internationally recognized World Health Organization (WHO) lymphoma classification introduced in 2001. Cases coded in International Classification of Diseases for Oncology, Second Edition (ICD-O-2), were converted to ICD-O-3 for WHO subtype assignment. Age-specific and age-adjusted rates were compared by sex and race (white, black, Asian). Age-adjusted trends in incidence were estimated by sex and race using weighted least squares log-linear regression. Diverse incidence patterns and trends were observed by lymphoid neoplasm subtype and population. In the elderly (75 years or older), rates of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma increased 1.4% and 1.8% per year, respectively, whereas rates of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per year. Although whites bear the highest incidence burden for most lymphoid neoplasm subtypes, most notably for hairy cell leukemia and follicular lymphoma, black predominance was observed for plasma cell and T-cell neoplasms. Asians have considerably lower rates than whites and blacks for CLL/SLL and Hodgkin lymphoma. We conclude that the striking differences in incidence patterns by histologic subtype strongly suggest that there is etiologic heterogeneity among lymphoid neoplasms and support the pursuit of epidemiologic analysis by subtype.

7 December 2005 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
LMLindsay M. Morton
Lindsay M. Morton
JCJack Cahill
Jack Cahill
PHPatricia Hartge
Patricia Hartge
Self-selection bias may threaten the internal validity of epidemiologic studies. Studies with a low level of participation are particularly vulnerable to this bias, and commentators note apparent declines in participation in recent years. The authors therefore conducted a retrospective review to survey the practice of reporting participation in epidemiologic studies, to assess changes in participation over time, and to evaluate the impact of increased biologic specimen collection on participation. The authors abstracted selected study characteristics from 355 peer-reviewed, original, analytic-epidemiology research articles published from January 1 to April 30, 2003, in 10 high-impact general epidemiology, public health, and medical journals. At least some information regarding participation was provided in 59% of cross-sectional studies, 44% of case-control studies, and 32% of cohort studies. Participation appears to have declined during 1970–2003 for all study designs. Participation declined most steeply for controls in population-based, case-control studies (−1.86% per year, 95% confidence interval: −3.03, −0.69), with steeper declines after 1990. Proportionately more studies collected biologic specimens over time, particularly for cohort and case-control study designs (ptrend = 0.06 and 0.03, respectively), yet participation was reported separately for the biologic specimen study component in only 27% of studies. The authors conclude that epidemiologists need to address declining participation and to report participation consistently, including for biologic specimen collection.

15 July 2007 in Blood
Verified
Journal Article
Open access
PDF file
LMLindsay M. Morton
Lindsay M. Morton
JTJennifer J. Turner
Jennifer J. Turner
JCJames Cerhan
James Cerhan
MLMartha S. Linet
Martha S. Linet
PTPatrick A. Treseler
Patrick A. Treseler
DWDennis D. Weisenburger
Dennis D. Weisenburger
Recent evidence suggests that there is etiologic heterogeneity among the various subtypes of lymphoid neoplasms. However, epidemiologic analyses by disease subtype have proven challenging due to the numerous clinical and pathologic schemes used to classify lymphomas and lymphoid leukemias over the last several decades. On behalf of the International Lymphoma Epidemiology Consortium (InterLymph) Pathology Working Group, we present a proposed nested classification of lymphoid neoplasms to facilitate the analysis of lymphoid neoplasm subtypes in epidemiologic research. The proposed classification is based on the World Health Organization classification of lymphoid neoplasms and the International Classification of Diseases–Oncology, Third Edition (ICD-O-3). We also provide a translation into the proposed classification from previous classifications, including the Working Formulation, Revised European-American Lymphoma (REAL) classification, and ICD-O-2. We recommend that epidemiologic studies include analyses by lymphoma subtype to the most detailed extent allowable by sample size. The standardization of groupings for epidemiologic research of lymphoma subtypes is essential for comparing subtype-specific reports in the literature, harmonizing cases within a single study diagnosed using different systems, as well as combining data from multiple studies for the purpose of pooled analysis or meta-analysis, and will probably prove to be critical for elucidating etiologies of the various lymphoid neoplasms.

1 August 2014 in JNCI Monographs
Verified
Journal Article
Open access
PDF file
LMLindsay M. Morton
Lindsay M. Morton
SSSusan L. Slager
Susan L. Slager
JCJames R. Cerhan
James R. Cerhan
SWSophia S. Wang
Sophia S. Wang
CVClaire Vajdic
Claire Vajdic
JSJoshua N. Sampson
Joshua N. Sampson
Non-Hodgkin lymphoma (NHL) comprises biologically and clinically heterogeneous subtypes. Previously, study size has limited the ability to compare and contrast the risk factor profiles among these heterogeneous subtypes. We pooled individual-level data from 17 471 NHL cases and 23 096 controls in 20 case–control studies from the International Lymphoma Epidemiology Consortium (InterLymph). We estimated the associations, measured as odds ratios, between each of 11 NHL subtypes and self-reported medical history, family history of hematologic malignancy, lifestyle factors, and occupation. We then assessed the heterogeneity of associations by evaluating the variability (Q value) of the estimated odds ratios for a given exposure among subtypes. Finally, we organized the subtypes into a hierarchical tree to identify groups that had similar risk factor profiles. Statistical significance of tree partitions was estimated by permutation-based P values (PNODE). Risks differed statistically significantly among NHL subtypes for medical history factors (autoimmune diseases, hepatitis C virus seropositivity, eczema, and blood transfusion), family history of leukemia and multiple myeloma, alcohol consumption, cigarette smoking, and certain occupations, whereas generally homogeneous risks among subtypes were observed for family history of NHL, recreational sun exposure, hay fever, allergy, and socioeconomic status. Overall, the greatest difference in risk factors occurred between T-cell and B-cell lymphomas (PNODE < 1.0×10−4), with increased risks generally restricted to T-cell lymphomas for eczema, T-cell-activating autoimmune diseases, family history of multiple myeloma, and occupation as a painter. We further observed substantial heterogeneity among B-cell lymphomas (PNODE < 1.0×10−4). Increased risks for B-cell-activating autoimmune disease and hepatitis C virus seropositivity and decreased risks for alcohol consumption and occupation as a teacher generally were restricted to marginal zone lymphoma, Burkitt/Burkitt-like lymphoma/leukemia, diffuse large B-cell lymphoma, and/or lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Using a novel approach to investigate etiologic heterogeneity among NHL subtypes, we identified risk factors that were common among subtypes as well as risk factors that appeared to be distinct among individual or a few subtypes, suggesting both subtype-specific and shared underlying mechanisms. Further research is needed to test putative mechanisms, investigate other risk factors (eg, other infections, environmental exposures, and diet), and evaluate potential joint effects with genetic susceptibility.

1 May 2014 in American Society of Clinical Oncology Educational Book
Verified
Journal Article
Closed access
PDF file
LMLindsay M. Morton
Lindsay M. Morton
KOKenan Onel
Kenan Onel
RCRochelle E. Curtis
Rochelle E. Curtis
EHEric A. Hungate
Eric A. Hungate
GAGregory T. Armstrong
Gregory T. Armstrong
As the population of cancer survivors has increased and continues to age, the occurrence of second cancers has risen dramatically—from 9% of all cancer diagnoses in 1975–1979 to 19% in 2005–2009. The Childhood Cancer Survivor Study, a cohort of more than 14,000 childhood cancer survivors with detailed exposure data and long-term follow-up, has substantially contributed to our understanding of the roles of radiotherapy and chemotherapy in second cancer occurrence. In particular, dose-related risks have been demonstrated for second cancers of the breast, thyroid, central nervous system, gastrointestinal tract, and sarcomas following radiation. Cytotoxic chemotherapy—which has long been known to be leukemogenic—also appears to contribute to risk for a range of other second cancer types. Individuals who develop a second cancer are at particularly high risk for developing additional second cancers. A genome-wide association study of survivors of Hodgkin lymphoma who received radiotherapy identified a locus on chromosome 6q21 as being associated with second cancer risk, demonstrating that recent advances in genomics are likely to prove invaluable for elucidating the contribution of genetic susceptibility to second cancer etiology. Among adults, risk of second cancers varies substantially by type of first and second cancer, patient age, and prevalence of second cancer risk factors, including primary cancer treatments, environmental and lifestyle exposures, and genetic susceptibility. Further research is needed to quantify second cancer risks associated with specific etiologic factors and to identify the patients at highest risk of developing a second cancer to target prevention and screening efforts.

1 March 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
LMLindsay M. Morton
Lindsay M. Morton
GDGraça M. Dores
Graça M. Dores
SSSara J. Schonfeld
Sara J. Schonfeld
MLMartha S. Linet
Martha S. Linet
BSByron S. Sigel
Byron S. Sigel
RCRochelle E. Curtis
Rochelle E. Curtis
The 21st century has seen substantial changes in the agents and clinical approaches to cancer chemotherapy, with corresponding improvements in prognosis for many cancers.1 However, the longer-term balance of benefits and risks of new treatment approaches often are not well understood because clinical trials for many cancers lack sufficient sample size and long-term patient follow-up. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a clonal hematopoietic stem cell neoplasm that can transform to AML, are rare, usually fatal complications of cancer therapy. Certain alkylating agents (eg, melphalan), platinum compounds (eg, cisplatin), and topoisomerase II inhibitors (eg, etoposide) have been reported to confer more than 5-fold increased risks for therapy-related MDS or AML (tMDS/AML), whereas other alkylating agents have lower risks (eg, cyclophosphamide), and other classes of agents, such as fluoropyrimidines (eg, fluorouracil), have no apparent association.2-4 Radiotherapy has been associated with tMDS/AML, although the exact magnitude of risk is unclear.5